We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Lipoxygenase Pathway Receptor Expression in Ovarian Cancer.
- Authors
Rocconi, Rodney P.; Kirby, Tyler O.; Seitz, Robert S.; Beck, Rod; Straughn Jr., J. Michael; Alvarez, Ronald D.; Huh, Warner K.
- Abstract
Objective: To determine the expression of lipoxygenase (LOX) pathway receptors in ovarian cancer as a potential target for anti-LOX-based therapy. Study design: Paraffin-embedded tumor samples from epithelial ovarian cancer patients were used to construct tissue microarrays to stain for the proposed sites of inhibition of a LOX inhibitor (5-LOX, LTB4-BLT1, and LTB4-BLT2). Results: 245 samples were available for interpretation. Strong expression was demonstrated in 45%, 34%, and 6% of ovarian cancer for LTB4-BLT2, LTB4-BLT1, and 5-LOX, respectively. Expression of LTB4-BLT2 correlated with advanced stage III/IV disease (P = .05), suboptimal debulking (P = .07), and platinum resistance (P = .03). No correlation was seen with regard to disease-free survival. Conclusions: LOX pathway receptor expression was found in the majority of cancers evaluated. Additionally, LTB4-BLT2 expression portends worse clinical parameters for ovarian cancer. Thus, further investigation on the role of LOX pathway in ovarian cancer is warranted.
- Subjects
LIPOXYGENASES; OVARIAN cancer; LEUKOTRIENES; THERAPEUTICS; OXYGENASES
- Publication
Reproductive Sciences, 2008, Vol 15, Issue 3, p321
- ISSN
1933-7191
- Publication type
Article
- DOI
10.1177/1933719108316390